Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women’s breast aesthetics and reconstruction, has announced the appointment of Taylor Harris to its Board of Directors. Company leadership expressed strong confidence in Harris, with Chairman Nick Lewin noting that his deep medical aesthetics expertise and history of shareholder value creation will be tremendous assets as the company enters its next phase of global market growth.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
Harris brings over 25 years of extensive experience in corporate finance, executive leadership, and board governance within the healthcare and life sciences sectors. He currently serves on the board of Procept BioRobotics and has previously held director positions at Omada Health and Endologix. Most recently, Harris served as the Chief Executive Officer of Cutera, Inc.
Throughout his career, Harris has a proven track record of guiding medical technology firms through major, high-value acquisitions. He previously served as Chief Financial Officer at MyoKardia during its $13.1 billion acquisition by Bristol Myers Squibb, and held the CFO role at Zeltiq Aesthetics and Thoratec Corporation during their respective acquisitions. His foundational career also includes over a decade in healthcare equity research and investment banking at JPMorgan Chase & Co.
